Anavex Life Sciences Corp (AVXL)

[12x]

The first column of the EMA link indicates the submission deadline, while the second column shows the corresponding 'start date.' The EMA pre-announces these deadlines and start dates for the year. For applications submitted by each deadline, the EMA typically assigns the start date as the acceptance date. Companies may issue press releases at the time of submission, acceptance, or both, often aligning with the EMA’s pre-announced deadlines or start dates.

When applications encounter issues and cannot be accepted on the corresponding start date, they are often reassigned to the next available start date.

In this case, the November 28 start date applies to applications submitted by the November 11 deadline, while the December 27 start date is for applications submitted by November 25. Missing the November 25 deadline would push the next opportunity to the January 6, 2025 deadline, with a start date of January 23, 2025.

https://www.ema.europa.eu/en/medicines/medicines-human-use-under-evaluation#monthly-lists-2024-64952